Drug Target Review
NOVEMBER 17, 2023
Professor Alan Trounson AO CEO, Executive Director, Cartherics Alan is the past President of the Californian Institute for Regenerative Medicine (2007-2014), the Californian state’s $3 billion stem cell agency driving research in stem cell biology and facilitating the translation of stem cell discoveries into clinical therapies.
Drug Target Review
NOVEMBER 1, 2023
Andrew McCarthy Andrew is a Team Leader at EMBL Grenoble since 2007. He has over 25 years of research experience in the application of structural biology techniques to understand protein function at the molecular level. His team mainly studies proteins involved in cell signalling and neuronal development. 2017;2017:1–15.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
AUGUST 10, 2023
When bound to GRP78, ID2 loses its inhibitory function, leading to increased invasiveness of cancer cells. Implications for cancer therapeutics and beyond These findings have wide-ranging implications for cancer treatment and cell biology research. IOS Press; 2007 [cited 2023 Jul 26]. Available from: [link]
BMG Labtech
JANUARY 23, 2024
4 The crystal structure of the luciferase from Renilla reniformis was determined in 2007. 5 The usefulness of bioluminescence as a tool to study biology at the molecular level jump started a search for alternative luciferases, in many cases from other marine organisms that were bioluminescent.
The Pharma Data
DECEMBER 31, 2020
It is a big improvement over the first reference assembled in 2007, and they believe it can help analyze and answer fundamental questions in molecular genetics, cell biology and physiology, not just in rhesus macaques, but in humans and other primates and mammals.
The Pharma Data
OCTOBER 22, 2020
months (Vermorken et al, JCO 2007). Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. overall response rate, a median time to progression of 2.3 months and a median overall survival of 5.8
New Drug Approvals
JANUARY 9, 2024
As such, it has been proposed that inhibiting CDK7 would provide a potent means of inhibiting cell cycle progression, which may be especially relevant given that there is compelling evidence from gene knockout studies in mice for lack of an absolute requirement for CDK2, CDK4 and CDK6 for the cell cycle at least in most cell types (M alumbres et al.,
Expert insights. Personalized for you.
118 
Let's personalize your content